126
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia

ORCID Icon, , , , , , , , & show all
Pages 491-494 | Received 13 Sep 2021, Accepted 08 Oct 2021, Published online: 20 Oct 2021
 

Acknowledgments

We would like to thank all members of our team. DK collected, analyzed the data and wrote the manuscript. YL, ZF, LY, JS, ZW provided clinical care and analyzed clinical data. MH performed lab examinations. JY, ZY and DW designed the study, identified, consented and treated the patient as principal investigator.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was supported by research grants from National Natural Science Foundation of China [81600105, 81730003], National Science and Technology Major Project [2017ZX09304021], National Key R&D Program of China [2019YFC0840604, 2017YFA0104502], Key R&D Program of Jiangsu Province [BE2019798], Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Jiangsu Medical Outstanding Talents Project [JCRCA2016002], Jiangsu Provincial Key Medical Center [YXZXA2016002], Suzhou Science and Technology Program Project [SLT201911].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.